215 related articles for article (PubMed ID: 22465920)
1. [Methylarginies-induced endothelial dysfunction in chronic kidney disease].
Kimura K
Yakugaku Zasshi; 2012; 132(4):443-8. PubMed ID: 22465920
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
[TBL] [Abstract][Full Text] [Related]
3. New pathways to renal damage: role of ADMA in retarding renal disease progression.
Ueda S; Yamagishi S; Okuda S
J Nephrol; 2010; 23(4):377-86. PubMed ID: 20349427
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease.
Bartnicki P; Kowalczyk M; Franczyk-Skóra B; Baj Z; Rysz J
Curr Vasc Pharmacol; 2016; 14(4):360-7. PubMed ID: 26759218
[TBL] [Abstract][Full Text] [Related]
5. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
6. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
Lentz SR; Rodionov RN; Dayal S
Atheroscler Suppl; 2003 Dec; 4(4):61-5. PubMed ID: 14664904
[TBL] [Abstract][Full Text] [Related]
7. ADMA and oxidative stress.
Sydow K; Münzel T
Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine.
Kajimoto H; Kai H; Aoki H; Yasuoka S; Anegawa T; Aoki Y; Ueda S; Okuda S; Imaizumi T
Kidney Int; 2012 Apr; 81(8):762-8. PubMed ID: 22297680
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Böger RH
Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
11. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
Baylis C
Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
13. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
Liu X; Xu X; Shang R; Chen Y
Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
Ueda S; Yamagishi S; Kaida Y; Okuda S
Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585
[TBL] [Abstract][Full Text] [Related]
16. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
17. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
18. ADMA: its role in vascular disease.
Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.
Mihout F; Shweke N; Bigé N; Jouanneau C; Dussaule JC; Ronco P; Chatziantoniou C; Boffa JJ
J Pathol; 2011 Jan; 223(1):37-45. PubMed ID: 20845411
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patients.
Ashokachakkaravarthy K; Rajappa M; Parameswaran S; Satheesh S; Priyadarshini G; Mohan Raj PS; Revathy G; Priyadarssini M
Int Urol Nephrol; 2020 Jul; 52(7):1321-1328. PubMed ID: 32409974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
